Mark Albertini is an Oncology physician affiliated with University of Wisconsin–Madison. OpenAlex indexes 191 publications with 5,133 citations (h-index 37); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
600 Highland Ave
Madison, WI 537920001
Telephone
608-265-1700Provider last certified this registry record 14 Jan 2021.
Clinical trials
- IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
Sponsor: University of Wisconsin, Madison
- Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma
Sponsor: University of Wisconsin, Madison
- Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
Sponsor: University of Wisconsin, Madison
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
NIH funding
5 NIH research awards on record, funded 1987–2026 per NIH RePORTER. The latest:
- Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanoma
Wm S. Middleton Memorial Veterans Hosp
FY2026I01BX003916 - Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanoma
Wm S. Middleton Memorial Veterans Hosp
FY2023I01BX003916 - Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanoma
Wm S. Middleton Memorial Veterans Hosp
FY2022I01BX003916
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
Journal of the National Comprehensive Cancer Network
2024 - NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021
Journal of the National Comprehensive Cancer Network
2021 - Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
Journal for ImmunoTherapy of Cancer
2021
Similar KOLs
Other experts from the same institution or the same specialty.
William Busse, MD
University of Wisconsin–Madison
David Andes, MD
University of Wisconsin–Madison
Neil Binkley, MD
University of Wisconsin–Madison
Robert Lemanske, MD
University of Wisconsin–Madison
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”